Endocrinologic and Metabolic Drugs Advisory Committee will discuss new drug application (NDA) 202293 dapagliflozin (FDA
Diabetes News Service
Endocrinologic and Metabolic Drugs Advisory Committee will discuss new drug application (NDA) 202293 dapagliflozin (FDA
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales